Kurse werden geladen...
Prognose
Kaufen | 0 |
Halten | 0 |
Verkaufen | 1 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 6 / 18 |
Levermann-Strategie | 1 / 13 |
News
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company's Executive Committee. This appointment is part of EUROAPI's ongoing FOCUS-27 transformation plan and reinforces its position as a European leader in the API and CDMO sectors.» Mehr auf globenewswire.com
EUROAPI moves into a new chapter with new Governance and Leadership
Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company's Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief Executive Officer. Consequently, upon the recommendation of the Nominations and Compensation Committee, the Board has appointed Emmanuel Blin as Chair of the Board and David Seignolle as Chief Executive Officer, effective immediately. In response to the new governance, Elizabeth Bastoni stepped down as Independent Lead Director; she remains Chair of the Nominations and Compensation Committee. » Mehr auf globenewswire.com
Olivier Falut appointed EUROAPI's Chief Financial Officer
Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI's Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 468,30 Mio | - |
Bruttoeinkommen | 44,40 Mio | - |
Nettoeinkommen | −95,80 Mio | - |
EBITDA | −77,40 Mio | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 251,90 Mio€ |
Anzahl Aktien | 95,23 Mio |
52 Wochen-Hoch/Tief | 3,41€ - 2,10€ |
Dividenden | Nein |
Beta | 0,69 |
KGV (PE Ratio) | −2,16 |
KGWV (PEG Ratio) | −0,04 |
KBV (PB Ratio) | 0,29 |
KUV (PS Ratio) | 0,31 |
Unternehmensprofil
Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.
Name | EUROAPI |
CEO | David Seignolle |
Sitz | Paris, Frankreich |
Website | |
Börsengang | |
Mitarbeiter | 3.187 |
Ticker Symbole
Börse | Symbol |
---|---|
Euronext | EAPI.PA |
Pnk | EAPIF |
Frankfurt | 940.F |
Düsseldorf | 940.DU |
London | 0EAP.L |
Paris | EAPI.PA |
München | 940.MU |
Assets entdecken
Shareholder von EUROAPI investieren auch in folgende Assets